Introduction
The ataxia telangiectasia mutated and RAD3-related (ATR) protein kinase is a master operator in genome maintenance through coordinating DNA replication, DNA repair, and cell cycle transition (de Klein et al., 2000; Hekmat-Nejad et al., 2000; Saldivar et al., 2017) . Single-stranded DNA (ssDNA) produced at sites of stressed or stalled replication forks is bound by replication protein A (RPA) complex, which activates ATR with the help of ATR interacting protein (ATRIP) (Bomgarden et al., 2004; Cortez et al., 2001; Zou and Elledge, 2003) . The activated ATR further initiate a series of cellular processes including replication stress response and DNA repair. Among these, a critical role of ATR is the control of cell cycle checkpoint.
ATR activates its downstream CHK1 kinase, which further suppresses cyclin-dependent kinases (CDKs) to prevent cells with DNA lesions to entry mitosis (Abraham, 2001; Liu et al., 2000; Sorensen and Syljuasen, 2012) . A second key function of ATR is to prevent replication catastrophe through stabilizing stressed replication fork (Cha and Kleckner, 2002; Costanzo et al., 2003; Hekmat-Nejad et al., 2000; Luciani et al., 2004) . Moreover, ATR activity is important for various DNA damage repair pathways, such as homologous combination repair (HR) and interstrand crosslink (ICL) repair (Buisson et al., 2017; Collis et al., 2008; Fasullo and Sun, 2008; Wang et al., 2004; Zhu and Dutta, 2006) .
The multiple functions of ATR in coordinating the responses to replication stress and DNA damage make it a promising target for cancer therapy (Rundle et al., 2017; Williamson et al., 2016) . Tumors often harbor high replication stresses due to escalated proliferation, which may increase their need for ATR activity. Similarly, due to the roles of ATR in various DNA damage repair pathways, combination with ATR inhibitor may enhance the efficacy of chemotherapy and radiation therapy that directly or indirectly induce DNA lesions.
DNA interstrand crosslink (ICL) is considered as one of the most toxic DNA lesions because DNA double helix is covalently linked and DNA replication and transcription are absolutely blocked (Huang et al., 1995; Knipscheer et al., 2009) . Repair of ICL is a complex process, which requires the coordination of several distinct DNA repair pathways, including Fanconi anemia (FA) pathway, Homologous Since many of these events are regulated by ATR kinase, ATR inhibition sensitizes cells to a variety of DNA damage-inducing agents including cisplatin and mitomycin C (MMC) that induce ICLs.
In order to understanding various cellular processes that require ATR activity in humans, several large-scale genetic screens have been conducted in human cells. Previous studies with RNA interference identified many genes when lost confer heightened sensitivity to ATR inhibition (Kwok et al., 2016; Mohni et al., 2014; Williamson et al., 2016) . The advance of CRISPR/Cas9-based screens further prompted us to perform genome-wide profiling of vulnerabilities to ATR inhibition (Wang et al., 2019) . These unbiased profiling of genes when lost may affect sensitivity to ATR inhibition is useful for at least two purposes.
First, these studies allow the identification of new genetic alternations and biomarkers that endow hypersensitivity of tumors to ATR inhibition, which can be exploited in clinic. Second, these studies also reveal novel genes that have functional and/or genetic interaction with ATR pathway.
In this study, we will focus on a previously uncharacterized gene C17orf53, whose loss led to increased sensitivity to ATR inhibition in our previous screen (Wang et al., 2019) . To date, human C17orf53 was only reported in few studies and the functions of C17orf53 remain largely unknown. A previous study indicated a potential relationship between C17orf53 SNPs and bone density (Styrkarsdottir et al., 2009) , while another recent study suggested that C17orf53 is a G2/M specific gene (Giotti et al., 2018) .
Here, we showed that C17orf53 is conserved in vertebrate and its expression associates with cell proliferation. Loss of C17orf53 induced aberrant DNA replication and pronounced ICL repair defect.
Moreover, C17orf53 functions independent of FA pathway in ICL repair. Its depletion impaired the loading of late HR factors. Furthermore, we showed that C17orf53 is ssDNA-and RPA-binding protein.
Collectively our data suggest that C17orf53 may act in a new pathway that promote ICL repair independent of FA pathway.
Results

C17orf53 loss sensitizes cells to ATR inhibition
We recently reported genome-wide CRISPR screens for profiling genes that affect cellular response to ATR inhibition (Wang et al., 2019) (Figure 1A) . In this study, many genes involved in DNA replication or replication-related DNA repair pathways were enriched, which include FA, HR and NER pathways ( Figure 1B) . We found 24 candidate genes correlated robustly with response to ATR inhibition, with 18 genes whose loss induced hypersensitivity to ATRi and 7 genes whose loss induced resistance to ATRi ( Figure 1C ). Some of these candidate genes have been already reported by us and others (Cotta-Ramusino et al., 2011; Lee et al., 2007; Ruiz et al., 2016; Wang et al., 2019) .
We focused on an uncharacterized gene C17orf53, loss of which induced hypersensitivity to ATR inhibition, since significant dropout of sgRNAs targeting this gene was noted in ATR inhibitor treated group ( Figure 1D ). We first confirmed these screening results with a different gene depletion method. Using shRNAs, we efficiently knocked down C17orf53 in 293A cells, which were validated in both mRNA and protein levels ( Figure 1E and Supplementary Figure 1A ). Cell survival assays showed that the C17orf53 knock-down cells were sensitive to treatment with two different ATR inhibitors ( Figure 1F and Supplementary Figure 1B ), further confirming that C17orf53 is a determinant of ATRi sensitivity.
On molecular levels, ATR inhibition induced dramatic increase of -H2A.X in C17orf53 knockdown cells ( Figure 1G) . Moreover, -H2A.X and 53BP1 foci were also significantly increased in C17orf53 knock-down cells upon ATR inhibitor treatment ( Figure 1H , I), indicating more DSBs were generated due to depletion of C17orf53. All these results suggest a possible function of C17orf53 in genome maintenance.
Furthermore, as genes co-essential with ATR inhibition usually participate in DNA replication or repair (Rundle et al., 2017; Saldivar et al., 2017; Wang et al., 2019) , our data indicate that C17orf53 may function in these processes.
C17orf53 is a conserved gene involved in cell proliferation
C17orf53 is highly conserved in vertebrates, which is schematically depicted in Figure 1J (please also see Supplementary Figure 1C for sequence alignment). While the function of C17orf53 remains unknown, a previous study indicated C17orf53 SNP correlates with BMD disease (Styrkarsdottir et al., 2009 ). Tissue expression profiling showed C17orf53 is highly expressed in bone marrow and testis ( Supplementary Figure 2A) , both of which are highly proliferative adult tissues, indicating a potential correlation between C17orf53 expression and cell proliferation.
To examine C17orf53 expression in tumors (hyper-proliferating cells) and normal tissues (with limited proliferating cells), we first screened C17orf53 expression profiles in a broad number of cancers ( Figure 2A ). We found C17orf53 was significantly up-regulated in most cancer types comparing with the relevant normal tissue (Supplementary Figure 2B) . Moreover, we found the expression of C17orf53 correlated robustly with numerous genes involved in DNA replication and replication-associated DNA repair processes such as HR and FA pathways in multiple datasets ( Figure 2B , C, D and Supplementary Figure 2C ). These data further implicated the relationship between C17orf53 expression and cell proliferation In 293A cells, C17orf53 is highly expressed in proliferating cells compared with that in quiescent cells ( Figure 2E) . A recent study suggested that C17orf53 is a highly expressed gene in S/G2 cell cycle phase (Giotti et al., 2018) . However, in our experiment, the C17orf53 protein level did not change significantly during cell cycle (Supplementary Figure 2E) . These findings indicate that C17orf53 is a cell proliferation related gene but its protein level is not significantly regulated during cell cycle.
It is also of note that the C17orf53 knock-down cells showed retarded cell growth and clonogenic ability, suggesting that C17orf53 is necessary for optimal cell proliferation. To confirm this result, we generated C17orf53 knock-out cells using CRISPR/Cas9 gene editing technology, which was validated by immunoblotting and genome sequencing ( Figure 2F and Supplementary Figure 2F ). Consistent with those observed in C17orf53 knock-down cells, the C17orf53-KO cells also showed slow cell growth and decreased clonogenic ability which could be rescued by reconstruction with ectopically expressed C17orf53 ( Figure 2G ).
The nice correlation of C17orf53 with numerous genes required for faithful DNA replication ( Figure 2B , C, D and Supplementary Figure 2C ) implied a similar role for C17orf53. Thus, we checked DNA replication in C17orf53 KO cells. As shown in Figure 2H , although C17orf53 KO cells showed similar cell cycle distribution as that of WT cells, BrdU incorporation was reduced in C17orf53 KO cells.
DNA fiber assay further confirmed slowed replication fork progression in C17orf53 KO cells ( Figure 2I , J). These findings suggest loss of C17orf53 may affect DNA replication, which may be one of the reasons that these cells are hypersensitive to ATR inhibition.
C17orf53 depleted cells show profound ICL repair defect
To gain more insight into C17orf53 functions, we tested the sensitivity of C17orf53 KO cells to treatment with a variety of DNA-damaging agents. We further confirmed that loss of C17orf53 sensitized cells to ATR inhibition and Chk1 inhibition ( Figure 3A and Supplementary Figure 3A ). Besides, C17orf53 KO cells showed hypersensitive to MMC treatment, but not to other agents such as IR, UV, HU and CPT ( Figure 3A and Supplementary Figure 3A ). Compared to WT cells, C17orf53 KO cells showed significant G2/M arrest upon MMC treatment ( Figure 3B ). Moreover, MMC treatment induced exacerbated DSB checkpoint activation as indicated by the dramatic increase of pRPA2 in C17orf53 KO cells, while neither HU nor CPT treatment could induce such dramatic change in C17orf53 KO cells ( Figure 3C ). This result was further confirmed with treatment of different doses of MMC, which showed pPRA2 and H2A.X levels were significantly increased in C17orf53 KO cells upon MMC treatment ( Figure 3D ). We also generated C17orf53KO U2OS cells. Similar to C17orf53KO 293A cells, MMC treatment could induce dramatic G2/M arrest and significant pRPA2 increase in C17orf53 depleted U2OS cells ( Supplementary Figure 3B, C) . Moreover, the luciferase based ICL repair reporter assay showed that, comparing to WT cells, C17orf53 KO cells showed decreased ability to repair the crosslink in the reporter plasmid while ectopic expression of C17orf53 could partially rescue it (Supplementary 3D, E).
These results above showed that C17orf53 depleted cells harbored profound defects in response to ICLinducing agent, suggesting a function of C17orf53 in ICL repair.
C17orf53 functions in the late stage of ICL repair that is downstream of FANCD2/RPA/RAD51 ICL repair is a complex process that requires the action of multiple DNA repair pathways [25] [26] [27] [28] [29] [30] .
To address the function of C17orf53 in this process, we treated WT or C17orf53 KO cells with MMC for 1 hour, released them from MMC, and then monitored DNA repair and DNA damage markers in these cells over time. We found that pRPA2 level was significantly increased in C17orf53 KO cells at any time point ( Figure 4A ). We also noticed that, in C17orf53 KO cells, H2A.X level kept increasing ( Figure 4A) , indicating an accumulation of DNA damage, which agrees with ICL repair defect caused by C17orf53 depletion. Consistent with the observations above, C17orf53 KO cells showed significant G2/M arrest even 48 hrs after MMC treatment (Supplementary 4A).
We also monitored repair kinetics through enumeration of FANCD2, RPA, RAD51 foci formation.
Immunostaining results showed, in C17orf53 KO cells, MMC treatment induced more FANCD2 foci at the early time point (8hrs), which also persisted much longer (48hrs) than those in WT cells ( Figure 4B ), suggesting that while the recruitment of FANCD2 was not affected by C17orf53 depletion, the ICL repair was impaired. Consistently, the monoubiquitination of FANCD2 and FANCI were not changed in C17orf53
KO cells comparing to WT cells. Similar to FANCD2 foci, RPA2 and RAD51 foci increased significantly at early time point (8hrs) and persisted much longer (48hrs) ( Figure 4C) , which again suggested that DNA resection indicated by RPA foci and the recruitment of RAD51 were not affected in C17orf53KO cells.
Together, these data suggest that C17orf53 functions in the late stage of ICL repair. We then used well-established reporter assays to monitor HR-or NHEJ-mediated capacity. We knocked down C17orf53 using siRNA in U2OS-DR-GFP cells and found that C17orf53 depletion led to a pronounced reduction in HR repair efficiency ( Figure 4E ). Interestingly, overall NHEJ repair efficiency was also impaired, albeit not as severe as HR repair, in these cells. These results suggest that defective ICL repair observed in C17orf53 depleted cells may be at least in part due to defective HR repair measured by these reporter assays.
However, the underlying mechanisms may be distinctively different, since C17orf53 KO cells did not show significant sensitive to IR or CPT treatment.
To gain further insight into the mechanism underlying ICL repair defect observed in C17orf53 depleted cells, we examined the chromatin loading of several repair factors and showed that the chromatin loading of Rev1, PolH, PCNA and RAD54 were compromised in C17orf53 KO cells ( Figure 4F ). Precisely how C17orf53 influences the loading of these repair factors remains to be elucidated.
CRISPR screens with DDR library in WT and C17orf53KO cells reveal genetic interaction between
C17orf53 and FA/HR pathway
We decided to take advantage of CRISPR screens to elucidate functional and/or genetic interaction between C17orf53 and other DDR genes. We created a targeted DDR library including 358 genes with known or suspected functions in DDR. As described in Figure 5A , WT cells or C17orf53 KO cells were infected with lentivirus encoding gRNAs targeting these DDR genes or lentivirus for the whole genome From the analysis of our screens, several themes emerged. We first noticed that depletion of TYMS, RFWD3, SCAI, HELQ, UBE2N genes inhibited growth in C17orf53 KO cells more than they did in WT cells, yielding a KO/WT ratio that is negative on a log2 scale; this ratio can also be negative for genes that promote growth of WT cell more than C17orf53KO cells (Figure 5 B , C, D). Several of these genes participate in DNA replication and RPA modification, suggesting the physiological function of C17orf53 may be involved in these processes, which is also consistent with our pervious observations. We also performed experiments using DDR library in WT cells or C17orf53 KO cells treated with DMSO or MMC ( Figure 5E ). When under MMC treatment, WT cells appeared to be more reliant on FA/HR/TLS pathways though loss of FA/HR/TLS pathways were also toxic to both WT and C17orf53 KO cells, while NHEJ pathway components were more essential for the survival of C17orf53 KO cells ( Figure   5F ). In the other words, these epistasis genetic screens under MMC treatment showed that loss of C17orf53 did not exacerbate ICL repair defects when FA/HR/TLS pathways were impaired, suggesting C17orf53 and FA/HR/TLS may operate together to promote ICL repair. In the absence of C17orf53, cells with compromised ICL repair appears to accumulate more DSBs as we demonstrated above and therefore these cells have an increased need for DSB/NHEJ repair for their survival.
C17orf53 contains a ssDNA-binding domain-DUF4539, which is essential for its function To clarify the molecular basis of C17orf53 function, we decided to further characterize C17orf53.
The highly conserved C-terminus of C17orf53 contains an unknown domain, DUF4539 ( Figure 6A) .
Bioinformatics analysis revealed a putative OB fold within DUF4539, suggesting that this domain may be able to bind to nucleotides (Supplementary Figure 5A, B) . EMSA assays using purified proteins showed that the C-terminus of C17orf53 containing the DUF4539 domain could preferentially bind to ssDNA, but not dsDNA ( Figure 6B ). Deletion of DUF4539 abolished the ssDNA-binding ability of the C-terminus of DUF4539 ( Figure 6B, C) . Reconstruction experiments in C17orf53 KO cells showed that ectopic expression of C17orf53-delDUF4539 induced more severe G2/M arrest upon MMC treatment ( Figure 6D ), suggesting ssDNA binding is essential for the function of C17orf53.
C17orf53 is a RPA binding protein.
We also performed TAP/MS to search for C17orf53-binding partners. As shown in Figure 7A , the C17orf53 interactome revealed enrichment of RPA complex. We conducted CoIP experiments and pull-down assays to validate the interaction between RPA complex and C17orf53. The CoIP experiments showed that C17orf53 could bind strongly to RPA1 and RPA2 ( Figure 7B ). Further in vitro pull-down assays demonstrated that RPA1 and RPA2 could bind directly to C17orf53 ( Figure 7C ). Further mapping results showed that C17orf53 binds to RPA1 and RPA2 through two separate RBMs at respectively Nand C-terminus of C17orf53 (Figure 7 D, E, F, G).
Discussion
In this study, we focused on a previously uncharacterized gene, C17orf53, which we identified as a gene that promotes viability especially in cells treated ATR inhibitor. We validated that loss of C17orf53 sensitized cells to ATR inhibition. We showed that C17orf53 expression correlates with cell proliferation.
C17orf53 may be important for cell proliferation due to its possible function in DNA replication.
Interestingly, C17orf53 depleted cells showed profound ICL repair defect. Further experiments revealed that C17orf53 functions at the late stage of ICL repair. Moreover, loss of C17orf53 led to aberrant HR repair, probably through impairing loading of several repair factors. In parallel, we performed functional CRISPR screens and revealed that C17orf53 may participate in ICL repair together with FA/HR proteins.
On molecular levels, C17orf53 is a ssDNA-binding and RPA-binding protein, both of which may be essential for its function in ICL repair. Taken together, our study revealed a new protein that functions in ICL repair. Further investigation of this process may reveal mechanistically how C17orf53 participates in ICL repair independent of FA and HR, the other two repair pathways known to be involved in ICL repair.
The high C17orf53 expression across many cancer types and the correlation of C17orf53 expression with poor diagnosis suggest a possibility that C17orf53 could be a reliable marker to discriminate pre-cancerous cells from normal cells. It is also of note that C17orf53 is a conserved protein, but seems to appear exclusively in vertebrate. Considering reduced DNA replication observed in cells with loss of C17orf53, it seems that the increased genome complexity may require more sophisticated regulation and thus the functions of C17orf53 during replication and repair. Nevertheless, the detailed mechanisms underlying the functions of C17orf53 in DNA replication and ICL repair remain to be further elucidated.
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Viability Assay
For cell growth assays, cells were seeded in 6-well plates (10 4 per well) and passaged every 3 days until cell numbers were determined. For clonogenic assays, cells were seeded in 6-well plates (400 cells per well) and continuously exposed to chemicals treatment for 14 days, beginning 24 h after seeding. Cells were fixed with 10% trichloroacetic acid and stained with sulphorhodamine B (Sigma-Aldrich). Colonies were counted manually. All cell survival assays were performed at least in triplicate.
Cell Cycle Analysis by Flow Cytometry
Cells were incubated with 10µM 5-bromo-2-deoxyuridin (BrdU) for 30min before fixation with 70% ethanol. BrdU was detected with BrdU antibody. Propidium iodide (PI) was used to measure DNA content.
Data were collected with BD C6 (Becton Dickinson) and analyzed with Flowjo.
Immunofluorescence staining Analysis
Cells were grown on coverslips for 24 h before treatment. After the indicated treatment, cells were fixed in 4% paraformaldehyde and permeablized with phosphate-buffered saline (PBS) with 0.5% Triton X-100.
Then, cells were incubated with primary antibodies diluted in PBS with 0.05% Triton X-100 and 1% BSA (PBST-BSA) for 1h at room temperature. After 3 washes with PBS, fluorescently labeled secondary antibodies in PBST-BSA were added for 1 h. Cells were then washed in PBS with Hoechst stain (1:10,000).
Slides were imaged at 40× on a Leica microscope.
Generation of knock-out cells pLentiCRISPRv2 was used to generate KO cells. Cells were transiently transfected with the indicated plasmids and selected using puromycin (2 mg/mL). Single cells were then plated into 96-well plates. After 10 days, clones were picked and checked by Western blotting.
DNA fiber Assay
Cells were labeled with 30 µM CIdU for 30 min, washed quickly twice with PBS and exposed to 250 µM IdU for another 30 min. Cells were harvested and resuspended in PBS. Cells were then lysed with lysis buffer (200 mM TrisHCL pH7.4, 50 mM EDTA, 0.5% SDS), and DNA fibers stretched onto glass slides.
The fibers were then denatured with 2.5 M HCL for 1 hr, washed with PBS and blocked with 2%BSA in PBST for 30 min. The fibers were stained with anti-BrdU antibodies recognizing CIdU and IdU. Slides were imaged at 40× on a Leica microscope.
siRNA Transfection
C17orf53 esiRNA and control siRNA were products of Sigma. 10nM of each siRNA was transfected to cells with Lipfectamin RNAiMAX Reagent (13778, Invitrogen) according to the manufacturer's instructions. Culture medium was changed 12 hr after the transfection.
RNA extraction, reverse transcription and real-time PCR
RNA samples were extracted with TRIZOL reagent (Invitrogen). Reverse transcription assay was performed by using the iScript cDNA Synthesis Kit (BioRad, Hercules, CA, USA) according to the manufacturer's instructions. Real-time PCR was performed by using Power SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, USA). For quantification of gene expression, the 2 − ΔΔCt method was used. Actin expression was used for normalization.
Immunoprecipitation (IP) and Mass Spectrometry
Expression plasmids were transfected to HEK293 suspension cells with polyethyleneimine. Cells were harvested 64 h after transfection and pellets were directly lysed with NTEN buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10% glycerol, 0.5% NP40, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 μg ml−1 leupeptin, 1 μg ml−1 aprotinin). The lysates were ultra-centrifuged at 15,000 rpm for 15 min and then the supernatant was incubated with Streptavidin beads for 3-4 h at 4 °C. The beads were washed four times with NETN buffer and washed with NETN with 2mg/ml biotin. The elution was then incubated with S-protein beads for 2hrs. Subsequently, the eluted complexes were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometry.
Western blotting
Cells were lysed in NET-N buffer (20 mM Tris [pH 7.6], 1 mM ethylenediaminetetraacetic acid, 1% NP40, 150 mM NaCl) supplemented with protease inhibitor cocktail tablets (Roche).
Gel-shift Assay
The DNA substrates were made by annealing oligos 60nt-f and 60nt-r, 30nt-f and 60nt-r, respectively. The 5ʹ ends of the oligo 60nt-f and 30nt-f were labeled with 32P using T4 polynucleotide kinase before annealing. In all, 5 nM 32P -labeled DNA subtracts and the indicated amount of proteins were incubated at 25 °C in 10 μl reaction buffer (20 mM HEPES at pH 7.5, 5 mM MgCl2, 100 mM KCl, 1 mM DTT, 0.05% Triton X-100, 100 μg ml−1 BSA and 5% glycerol) for 15 min. Reaction mixture was loaded and resolved on a 5% Tris-borate-EDTA (TBE) gel.
sgRNA screening
The TKOv3 library was a gift from Traver Hart lab, MD Anderson Cancer Center. DDR library was made by our lab (unpublished). The CRISPR screen was as describe before. In brief, 120 million 293A or C17orf53KO 293A cells were infected with the TKOv3 library lentiviruses or DDR library lentivirus at a low MOI (< 0.3). Twenty-four hours after infection, the medium was replaced with fresh medium containing puromycin (2 μg/mL). After selection, cells were split into 2 replicates containing ~20 million cells each, passaged every 3 days, and maintained at 200-fold coverage. At day 0 and every 3 days from day 6 to day 21, 25 million cells (> 300-fold coverage) were collected for genomic DNA extraction.
Genomic DNA was extracted from cell pellets using the QIAamp Blood Maxi Kit (Qiagen), precipitated using ethanol and sodium chloride, and resuspended in Buffer EB (10 mM Tris-HCl, pH 7.5). gRNA inserts were amplified via PCR using primers harboring Illumina TruSeq adapters with i5 and i7 barcodes as previously reported 38, and the resulting libraries were sequenced on an Illumina HiSeq 2500 system. The sequencing results were used for further analysis. MAGecK and Drug-Z analysis were used to calculate the difference between the DMSO-and MMC-treated groups.
HR-GFP and NHEJ-GFP reporter Assay 
Statistics
Statistical analyses were performed using GraphPad Prism software version 7.0. All of the statistical methods used are described in the main text. Each experiment was repeated twice or more, unless otherwise noted. Differences between groups were analyzed by the Student t-test. A P-value <0.05 was considered statistically significant.
Data availability
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